Considering that bufalin's molecular targets also include SRC‐3, which can increase MMP‐9 activity to enhance HCC cells migration and invasion, we examined the expression of SRC‐3 after bufalin treatment in HepG2 and MHCC97h cells. The gene discussed is NCOA3; the disease is hepatocellular carcinoma.